Wilson Sonsini Goodrich & Rosati has advised Forte Biosciences. Paul Hastings LLP has advised Guggenheim Securities and Barclays. Forte Biosciences, Inc., a clinical-stage biopharmaceutical company specializing...
Forte Biosciences Announces $150 Million Public Offering of Common Stock
Eli Lilly Acquires Ventyx Biosciences for $1.2 Billion to Enhance Inflammatory Disease Portfolio
Ropes & Gray has advised Eli Lilly and Company. Wilson Sonsini Goodrich & Rosati has advised Ventyx Biosciences. Gibson Dunn has advised Jefferies LLC as lead...
Philips Acquires SpectraWAVE to Expand Intravascular Imaging Portfolio
Wilson Sonsini Goodrich & Rosati has advised SpectraWAVE. Mintz has advised Royal Philips. Royal Philips has announced the acquisition of SpectraWAVE, a Massachusetts-based innovator specializing in...
GSK Acquires Worldwide License for Empirico’s COPD Candidate EMP-012
Wilson Sonsini Goodrich & Rosati has advised Empirico, and Davis Polk & Wardwell has advised GSK. GSK plc and Empirico Inc. have entered into a worldwide...
GHO Capital Partners to Acquire AI-Driven R&D Platform Scientist.com
Ropes & Gray, ClearView Healthcare Partners, West Monroe, and Deloitte have advised GHO Capital Partners. Union Square Advisors and Wilson Sonsini have advised Scientist.com. GHO Capital...
Forte Biosciences Announces $75 Million Public Offering of Common Stock and Pre-Funded Warrants
Wilson Sonsini Goodrich & Rosati has advised Forte Biosciences, Inc. on the offering, and Paul Hastings has advised the underwriters. Forte Biosciences, Inc., a clinical-stage biopharmaceutical...
Forte Biosciences’ $53 Million Equity Financing
Wilson Sonsini Goodrich & Rosati represented Forte Biosciences, while Paul Hastings advised TD Cowen in the transaction. Biopharmaceutical company, Forte Biosciences, announced an oversubscribed $53 million...
SpectraWAVE’s $50 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised SpectraWAVE on the transaction. SpectraWAVE, Inc., a medical imaging company, has announced raising $50 million in Series B funding round...
Forte Biosciences’ $25 Million Financing
Wilson Sonsini Goodrich & Rosati represented Forte Biosciences in the transaction. Forte Biosciences (NASDAQ: FBRX) announced key R&D updates for its product candidate FB-102 (a proprietary molecule...
Ventyx Biosciences’ $176.6 Million Private Placement of Common Stock
Wilson Sonsini Goodrich & Rosati advised Ventyx Biosciences on the deal while Goodwin Procter represented Redmile Group. Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company focused on...
Ventyx Biosciences’ $114 Million Equity Financing
Wilson Sonsini Goodrich & Rosati advised Ventyx Biosciences on the deal. Taylor Wessing advised Oppilan Pharma Limited and Zomagen Biosciences Limited. Ventyx Biosciences, a clinical-stage biotechnology...
Vividion Therapeutics’ $135 Million Series C Financing
Wilson Sonsini Goodrich & Rosati advised Vividion Therapeutics, Inc. and the lead investors on the deal. Vividion Therapeutics, Inc., a biotechnology company utilizing novel discovery technologies...